Compare Regeneron Pharmaceuticals Inc (REGN) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Williams-Sonoma, Inc. trades at $222.34 (market cap $26.04B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays the higher dividend (1.37%). Which is the better fit depends on your goals.
| REGN | WSM | |
|---|---|---|
Market Cap | $70.79B | $26.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $240.06 |
52-Week Low | $545.46 | $168.64 |
Enterprise Value | $64.74B | $26.88B |
Dividend Yield | 0.56% | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Williams-Sonoma (WSM) trades at $221.13, down 3.19% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has shown volatility. Recent earnings beats and consistent dividend payments highlight operational strength amid consumer discretionary sector challenges noted in recent financial media coverage.
The outlook is mixed with solid fundamentals and analyst consensus near current price, but risks include consumer spending sensitivity and competitive pressures. Upside potential exists if earnings momentum continues, yet macroeconomic headwinds and sector underperformance pose near-term challenges for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
